{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:12:52Z","timestamp":1794863572965,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA276865"],"award-info":[{"award-number":["R01 CA276865"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Reports of secondary malignancies after chimeric antigen receptor (CAR)-T and possible CAR-T derived malignant transformation necessitate caution. Here we describe a patient with diffuse large B-cell lymphoma who developed new lymphadenopathy 2.5 years after CAR-T in the context of COVID-19 infection with histopathologic features consistent with T-cell lymphoma (TCL). Deep molecular interrogation with genomic sequencing and single-cell spatial transcriptomics reveals a highly proliferative clonal T-cell population co-expressing CD4 and CD8 with biallelic TCR rearrangement and no evidence of the CAR construct. The expanded clonotype displayed T follicular helper (TFH) cell transcriptomic programs and occupies immune-excluded spatial niches within the lymph node, supportive of TFH-like neoplastic T cell behavior. Remarkably, the lymphadenopathy spontaneously resolved on interval imaging. Our data underscore the need for better understanding of post-CAR-T clonal T-cell lymphoproliferative disorders to avoid unnecessary treatment and higher specificity in diagnostic methods for TCL.<\/jats:p>","DOI":"10.1038\/s41467-025-62709-7","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:02:34Z","timestamp":1755010954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-181X","authenticated-orcid":false,"given":"Katie","family":"Maurer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-1344","authenticated-orcid":false,"given":"Jackson A.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-3135","authenticated-orcid":false,"given":"Nicholas J.","family":"Haradhvala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-4811","authenticated-orcid":false,"given":"Hariharan","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somkene","family":"Alakwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Dela Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loida","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsey","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Borji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip D.","family":"Michaels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Pinkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-3649","authenticated-orcid":false,"given":"Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"62709_CR1","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307\u20132315 (2023).","journal-title":"Blood"},{"key":"62709_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"62709_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"62709_CR4","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 38, 3805\u20133815 (2020).","journal-title":"J. Clin. Oncol."},{"key":"62709_CR5","unstructured":"Center for Biologics Evaluation & Research. FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. U.S. Food and Drug Administration https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous (2023)."},{"key":"62709_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"62709_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood.2022015728","volume":"140","author":"DHM Steffin","year":"2022","unstructured":"Steffin, D. H. M. et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood 140, 16\u201324 (2022).","journal-title":"Blood"},{"key":"62709_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong, E. A., Ruella, M., Schuster, S. J. & Lymphoma Program Investigators at the University of Pennsylvania Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N. Engl. J. Med. 384, 673\u2013674 (2021).","journal-title":"N. Engl. J. Med."},{"key":"62709_CR9","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood 138, 1391\u20131405 (2021).","journal-title":"Blood"},{"key":"62709_CR10","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood.2021010813","volume":"138","author":"DC Bishop","year":"2021","unstructured":"Bishop, D. C. et al. Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. Blood 138, 1504\u20131509 (2021).","journal-title":"Blood"},{"key":"62709_CR11","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047\u20132060 (2024).","journal-title":"N. Engl. J. Med."},{"key":"62709_CR12","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood 142, 6939\u20136939 (2023).","journal-title":"Blood"},{"key":"62709_CR13","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli, M. et al. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N. Engl. J. Med. 390, 2074\u20132082 (2024).","journal-title":"N. Engl. J. Med."},{"key":"62709_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","volume":"391","author":"G Kobbe","year":"2024","unstructured":"Kobbe, G. et al. Aggressive lymphoma after CD19 CAR T-cell therapy. N. Engl. J. Med. 391, 1217\u20131226 (2024).","journal-title":"N. Engl. J. Med."},{"key":"62709_CR15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"62709_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"62709_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"62709_CR18","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"62709_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689\u2013702 (2009).","journal-title":"J. Immunother."},{"key":"62709_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"62709_CR21","doi-asserted-by":"publisher","first-page":"1163190","DOI":"10.3389\/fonc.2023.1163190","volume":"13","author":"J Du","year":"2023","unstructured":"Du, J. et al. Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL). Front. Oncol. 13, 1163190 (2023).","journal-title":"Front. Oncol."},{"key":"62709_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1084\/jem.192.8.1165","volume":"192","author":"V Rochat-Steiner","year":"2000","unstructured":"Rochat-Steiner, V. et al. FIST\/HIPK3: a Fas\/FADD-interacting serine\/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation. J. Exp. Med 192, 1165\u20131174 (2000).","journal-title":"J. Exp. Med"},{"key":"62709_CR23","doi-asserted-by":"publisher","first-page":"13034","DOI":"10.1073\/pnas.1005997107","volume":"107","author":"SL Osborn","year":"2010","unstructured":"Osborn, S. L. et al. Fas-associated death domain (FADD) is a negative regulator of T-cell receptor-mediated necroptosis. Proc. Natl Acad. Sci. USA 107, 13034\u201313039 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"62709_CR24","doi-asserted-by":"publisher","first-page":"61485","DOI":"10.18632\/oncotarget.11370","volume":"7","author":"JL Mar\u00edn-Rubio","year":"2016","unstructured":"Mar\u00edn-Rubio, J. L. et al. Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma. Oncotarget 7, 61485\u201361499 (2016).","journal-title":"Oncotarget"},{"key":"62709_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-023-06837-4","volume":"625","author":"AJC Russell","year":"2024","unstructured":"Russell, A. J. C. et al. Slide-tags enables single-nucleus barcoding for multimodal spatial genomics. Nature 625, 101\u2013109 (2024).","journal-title":"Nature"},{"key":"62709_CR26","doi-asserted-by":"publisher","unstructured":"Kotliar, D. et al. Reproducible single cell annotation of programs underlying T-cell subsets, activation states, and functions. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.05.03.592310 (2024).","DOI":"10.1101\/2024.05.03.592310"},{"key":"62709_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.4049\/jimmunol.1800904","volume":"202","author":"NJ Schuldt","year":"2019","unstructured":"Schuldt, N. J. & Binstadt, B. A. Dual TCR T Cells: Identity Crisis or Multitaskers?. J. Immunol. 202, 637\u2013644 (2019).","journal-title":"J. Immunol."},{"key":"62709_CR28","doi-asserted-by":"crossref","unstructured":"Jang, H. J. et al. Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigens. J. Immunother. Cancer 11, e006472 (2023).","DOI":"10.1136\/jitc-2022-006472"},{"key":"62709_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4049\/immunohorizons.2200062","volume":"7","author":"EM Muhowski","year":"2023","unstructured":"Muhowski, E. M. & Rogers, L. M. Dual TCR-expressing T cells in cancer: how single-cell technologies enable new investigation. Immunohorizons 7, 299\u2013306 (2023).","journal-title":"Immunohorizons"},{"key":"62709_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"62709_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"62709_CR32","unstructured":"Lead Organizations: NCI Network Trial Development and Conduct. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"62709_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","volume":"29","author":"EM Parry","year":"2023","unstructured":"Parry, E. M. et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat. Med. 29, 158\u2013169 (2023).","journal-title":"Nat. Med."},{"key":"62709_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"62709_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"62709_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41592-018-0036-9","volume":"15","author":"A Taylor-Weiner","year":"2018","unstructured":"Taylor-Weiner, A. et al. DeTiN: overcoming tumor-in-normal contamination. Nat. Methods 15, 531\u2013534 (2018).","journal-title":"Nat. Methods"},{"key":"62709_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1443","volume":"41","author":"M Costello","year":"2013","unstructured":"Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).","journal-title":"Nucleic Acids Res."},{"key":"62709_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","volume":"18","author":"MJ Kluk","year":"2016","unstructured":"Kluk, M. J. et al. Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies. J. Mol. Diagn. 18, 507\u2013515 (2016).","journal-title":"J. Mol. Diagn."},{"key":"62709_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GXY Zheng","year":"2017","unstructured":"Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"62709_CR40","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41592-023-01943-7","volume":"20","author":"SJ Fleming","year":"2023","unstructured":"Fleming, S. J. et al. Unsupervised removal of systematic background noise from droplet-based single-cell experiments using CellBender. Nat. Methods 20, 1323\u20131335 (2023).","journal-title":"Nat. Methods"},{"key":"62709_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"62709_CR42","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1182\/blood.2024024381","volume":"144","author":"K Maurer","year":"2024","unstructured":"Maurer, K. et al. Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma. Blood 144, 2490\u20132502 (2024).","journal-title":"Blood"},{"key":"62709_CR43","doi-asserted-by":"crossref","unstructured":"Schubert, M.-L. et al. Assessment of CAR T cell frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel patients using duplex quantitative PCR. Cancers 12, 2820 (2020).","DOI":"10.3390\/cancers12102820"},{"key":"62709_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44137-7","volume":"15","author":"L Penter","year":"2024","unstructured":"Penter, L. et al. Integrative genotyping of cancer and immune phenotypes by long-read sequencing. Nat. Commun. 15, 32 (2024).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62709-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62709-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62709-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:00:42Z","timestamp":1757419242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62709-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62709"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62709-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"2 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.J. reports consultancy for Kite\/Gilead, BMS\/Celgene, Novartis, Instil Bio, ImmPACT Bio, Caribou Bio, Miltenyi, Ipsen, ADC Therapeutics, Abbvie, AstraZeneca, Morphosys, Synthekine, and Sana, and research funding from Kite\/Gilead and Pfizer. C.J.W. is an equity holder of BioNTech, Inc., receives research funding from Pharmacyclics, and is on the SAB of Repertoire, Adventris, Nature\u2019s Toolbox, Aethon Therapeutics. F.C. is an academic founder of Curio Bioscience and Doppler Biosciences, and a scientific advisor for Amber Bio. F.C.'s interests were reviewed and managed by the Broad Institute in accordance with their conflict-of-interest policies. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7462"}}